Watch Demo

South Korea Cardiovascular Drug Industry Outlook 2022 - 2026

See how South Korea Cardiovascular Drug performed compared to key markets such as Germany, Italy and Canada.

Key Market Indicators

Korean beta blocking medicine sales are forecast to reach $112.63 million by 2026. In 2021, sales in the country were $121.33 million, down 0.9% from the previous year. Since 2013, Korean sales have grown at an average rate of 2.6% annually. In 2021, the country came in sixth place in the rankings, with Spain in the top spot at $121.33 million. Italy, Canada and Australia followed in second, third and fourth place respectively.

Marketing Banner

South Korea Cardiovascular Drug Market Data and Forecasts

How much will South Korea Cardiovascular Drug Market grow to 2026?

Forecast: Diuretic Medicine Sales in South Korea
Forecast: Beta Blocking Medicine Sales in South Korea
Forecast: Diuretic Medicine Sales in South Korea
Forecast: Cardiovascular System Medicine Sales in South Korea
Forecast: Cardiac Glycosides Sales in South Korea
More in Cardiovascular Drug Industry for 2028

Improve your Knowledge with the latest Indicators and Trends